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Zinc and tetrathiomolybdate, effective, nontoxic drugs, have now been added to the treat-
ment of most phases of Wilson’s disease. Zinc is used for maintenance as well as treating
presymptomatic, pregnant, and pediatric patients. Tetrathiomolybdate is the choice for
patients presenting with neurologic diseases. J. Trace Elem. Exp. Med. 13:51–61,
2000. © 2000 Wiley-Liss, Inc.
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INTRODUCTION
Wilson’s disease is an inherited, autosomal recessive disease of copper accumu-
lation [1–3]. Patients present, generally between the ages of 10 and 40 years, with
liver disease, neurological abnormalities, psychiatric symptoms, or some combination
of these. The liver is the organ responsible for copper homeostasis. Humans take in
about 1.0 mg of copper/day, which is about 25% more than requirements [1]. The
liver excretes the excess in the bile for loss in the stool. Wilson’s disease patients are
not able to excrete excess copper in the bile [4–6] due to a mutation in a gene called
ATP7B [7–9], which is part of the liver’s excretory pathway for copper.
Wilson’s disease patients generally have a low blood ceruloplasmin (Cp). Ceru-
loplasmin contains six molecules of copper and is the main copper-containing protein
of the blood. A low blood Cp in Wilson’s disease seems to carry no special clinical
significance, since 10–20% of Wilson’s disease patients have a normal Cp, yet portray
the same spectrum and severity of symptoms and abnormalites as do patients with a
low Cp. We have hypothesized that the low blood Cp and the failure in copper balance
regulation are due to the same general mechanism [10]. In normal bile, but not in bile
from Wilson’s disease patients, we find copper-containing fragments of Cp molecules
[10]. These fragments are resistant to proteolytic digestion and provide a packaging
mechanism for copper to escape in the stool without reabsorption in the intestinal
tract. Thus we postulate that the product of ATP7B plays a role in the maturation of
Cp, possibly such as copper addition, and that this failure of Cp maturation in Wil-
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son’s disease leads to low secretion of Cp into blood and low excretion of Cp into bile,
the latter leading to loss of copper balance regulation [10].
Failure to recognize a possible diagnosis of Wilson’s disease in a patient who truly
has it is a worldwide problem. Physicians often fail to think of Wilson’s disease
because it is rare, because it can present with any one or a combination of a long list
of symptoms and because it can masquerade as any one of many diseases that are
much more common. The presenting symptoms and laboratory findings may suggest
viral hepatitis, chronic active hepatitis, cirrhosis (including alcoholic cirrhosis), and
liver failure [1–3]. Or the manifestations may include neurological symptoms, either
singly or in combinations, such as dysarthria, tremor, dystonia, incoordination, Par-
kinsonism, or other symptoms typical of a movement disorder [11]. To further con-
fuse the issue, the symptoms may be psychiatric in nature and include loss of ability
to focus on tasks, extremes of emotionality, depression, delusions or hallucinations,
and manic behavior. Thus, this plethora of modes of presentation causes Wilson’s
disease patients to be relatively hidden in much more common patient groups.
One of the keys in recognizing the possibility of Wilson’s is to use relative youth
to enhance index of suspicion. Many of the diseases with which Wilson’s is confused
are primarily diseases of people beyond 40 years, such as alcoholic cirrhosis, essential
tremor, and Parkinsonism. In patients age 40 or less, any of the abnormalities noted
above should cause the physician to think of the possibility of Wilson’s disease and
screen for it.
Which screening tests to use depends a little on the area of symptoms. In the
neurologic or psychiatric presentation, a slit-lamp exam for Kayser-Fleischer (KF)
[12,13] rings (copper deposits in the cornea) is very useful because this type of patient
almost always has KF rings. However, these rings are often absent in patients with the
hepatic presentation, or in presymptomatic patients. (Presymptomatic patients are
those usually identified by screening as a result of a diagnosis in a sibling. All full
siblings of an affected person are at 25% risk of having the disease in a presymp-
tomatic state. It is important to diagnose these patients because they should be treated
prophylactically).
The 24-hour urine copper is a very valuable screening tool in that all symptom-
atically presenting patients have values over 100mg (normal is 20–50) [1]. False
positives can occasionally be seen in long-standing or obstructive liver disease. Pre-
symptomatic patients may not always have reached 100 [1]. Their values can range
from 65 on up, and since gene carriers can have slightly elevated values, ranging from
75 on down, there is some overlap.
Blood ceruloplasmin (Cp) is low in about 90% of Wilson’s disease patients, but
some patients have normal Cp values. Since about 10% of gene carriers can have low
Cp values, this test should be used only to affect index of suspicion about the disease.
Definitive diagnosis of Wilson’s disease in some cases can be based on results of
one or more of the above tests plus the clinical picture. For example, a patient with
a typical neurologic picture who has KF rings needs no further diagnostic workup. A
patient with behavioral symptoms, KF rings, and an elevated (over 100mg/ 24 hours)
urine copper also has Wilson’s disease. In all patients in whom there is doubt, and in
most patients with liver disease, a liver biopsy with quantitative liver copper assay
should be carried out. This is the gold standard for diagnosis. Affected patients,
whether presymptomatic or not, will have values over 200mg/g dry weight of liver.
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Normal is 20–50, and gene carriers are never over 125. It is to be emphasized that the
copper must be assayed quantitatively. Copper stains are not reliable for diagnosis.
Treatment With Zinc and Tetrathiomolybdate
Table I provides an organizational framework for anticopper therapy in Wilson’s
disease. When we began work on Wilson’s disease a couple of decades ago, the two
available drugs were penicillamine and trientine. Notice that a drug of long-standing
use [14], penicillamine, is absent from Table I. Because of its toxicity [1], we almost
never use it for treating Wilson’s disease, the one exception being its possible use in
fulminant hepatic failure when a liver transplant is not available, or is refused.
Trientine [15], which like penicillamine is a chelator that causes increased urinary
excretion of copper, is a safer drug than penicillamine. It shares some of the same
toxicities as penicillamine, but at a lower frequency. As of now, it is one of the two
drugs we use for initial therapy of the hepatic presentation (Table I).
Our work has focused on the development of zinc and tetrathiomolybdate therapy
for Wilson’s disease, and we briefly review the use of these drugs.
Zinc Therapy
Our interest in using zinc as an anticopper drug in Wilson’s disease stemmed from
a serendipitous observation in sickle cell anemia. We were giving sickle cell patients
high doses of zinc to inhibit sickling [16], when we discovered that about 3 months
of therapy caused these patients to become mildly copper deficient [17,18]. As a
geneticist, I was aware of Wilson’s disease and the problems with penicillamine, and
it occurred to me that perhaps we could develop zinc as a safer alternative. We then
did copper balance and uptake studies with orally administered64copper in patients in
whom we temporarily stopped penicillamine and treated with the same dose and
regimen of zinc we had used for sickle cell anemia [19]. When these studies showed
that zinc therapy produced a negative copper balance and blocked64copper absorp-
tion, we began the step-by-step development of zinc as a therapy in Wilson’s disease
[20–35].
In our early work we had to choose a salt of zinc with optimal properties. Zinc
sulfate has been the standard salt used and was known to be well absorbed. However,
TABLE I. Organization of Anticopper Therapy in Wilson’s Disease and Drug of Choice
Category of patient Drug of choice
Initial Presentation (First 2–6 months)
Psychiatric Tetrathiomolybdate (2 months)
Neurologic Tetrathiomolybdate (2 months)






sulfate was known to be irritating to the stomach. We showed that zinc acetate was
equally well absorbed, whereas zinc carbonate was somewhat inferior [36]. We later
showed that zinc oxide is greatly inferior [37]. Thus all our work on Wilson’s disease
has been carried out with zinc acetate.
The copper balance and64copper uptake data [19–21] told us that at any one point
in time, i.e., during hospitalization, zinc controlled copper metabolism. But before we
could place patients on zinc for any extended period of time, particularly during
periods in the home environment, we needed monitoring tools that told us zinc was
controlling copper under these conditions. We found that measuring 24-hour urinary
excretion of copper was excellent for this purpose [23]. Without chelation therapy,
urinary excretion of copper is a reflection of body loading of copper. Thus this
variable gave us information on the cumulative effects of zinc therapy on reducing the
body burden of copper. We found that in well-complying patients, urinary excretion
of copper gradually decreases to a value <125mg/ 24 hours, which reflects good
control (normal is 20–50) [34].
Also useful is the nonceruloplasmin plasma copper value [23,34]. Ceruloplasmin
(Cp) contributes substantially to plasma copper, but this copper is nontoxic. So a
simultaneous measure of plasma copper and Cp is done and then the Cp copper
subtracted from the plasma copper [2]. This is done by subtracting 3mg of copper for
every mg of Cp. Thus in a patient with a plasma copper of 30mg/dl, and a Cp of 5
mg/dl, the 5 is multiplied by 3 to give 15mg Cp copper/dl. Then the 15 is subtracted
from 30 (total plasma copper) to give a value of 15mg/dl for nonceruloplasmin
plasma copper. Other names for this are “free copper” (although it’s not free), “avail-
able copper,” or “potentially toxic copper.” In normal persons, the nonceruloplasmin
plasma copper is around 10–15mg/dl. In untreated Wilson’s disease, this pool is
usually greatly expanded and is frequently 50 or higher. In our experience, when this
pool of copper is brought below 25, the patient is under good control [34].
As soon as we had monitoring tools in place, we began to determine appropriate
dose and dose regimens for zinc [20,25,27,31]. We established early that zinc had to
be separated from most foods and most beverages other than water to be maximally
effective. Thus we recommend separating zinc by at least 1 hour from the ingestion
of substances other than water.
To investigate dose and regimens, we used a combination of 10-day copper balance
studies and64copper uptake studies [20,25,27,31]. We placed patients on the regimen
to be studied for several weeks before the study to allow complete washout of former
therapies. With no therapy we saw an average of +0.25 mg/day positive copper
balance and high absorption of orally administered64copper. A dose as low as 25 mg
of zinc/day reduced the average positive balance significantly but did not consistently
control copper balance or64copper uptake. The same can be said for 25 mg × 2, 50
mg × 1 and 75 mg × 1. Interestingly, when we split the 75 mg daily dose into two or
three divided doses, such as 37.5 mg × 2 or 25 mg × 3,consistent control of copper
balance and64copper absorption was obtained; 50 mg × 2 and 50 mg × 3 were also
effective doses. To provide a safety margin, our standard recommended adult dose is
50 mg × 3 [1, 34].
The mechanism of zinc action on copper metabolism received attention in animal
studies by other investigators during the early years of zinc development as a therapy
for Wilson’s disease. The Cousins group in Florida [38, 39] and the Bremner group
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in Scotland [40] showed that zinc induces intestinal cell metallothionein, which has
a high affinity for copper, and prevents the serosal transfer of copper. The bound
copper goes into the stool as the mucosal cells of the intestine desquamate. Later, in
collaboration with the Cousins group, we showed that this mechanism is also valid in
Wilson’s disease patients [29]. Using intestinal biopsies to obtain samples for metal-
lothionein assay, we found that with zinc therapy, intestinal metallothionein levels
increased in concert with blockade of64copper absorption.
To evaluate the efficacy of zinc in Wilson’s disease, we set up a protocol that
required that all patients going on zinc therapy as their sole anticopper medication
have an initial copper balance study and64copper absorption study. Only with docu-
mentation that a given zinc regimen controlled copper did we feel safe in initiating
long-term therapy. In our view, to do otherwise in the early stages of a trial such as
this would be unethical, because known effective therapy (penicillamine and trientine)
was available. We monitored efficacy and possible toxicity in these patients by
following urine copper, liver copper, urine zinc, plasma zinc, nonceruloplasmin
plasma copper, neurologic and speech function scores, blood counts, and other routine
serum biochemical measures as safety variables at regular intervals. We used a mail-
in urine kit system to follow urine copper and zinc levels.
All patients started on zinc as part of this trial were followed and accounted for. In
this sense, this study has become by far the largest and longest scientifically per-
formed clinical trial of a therapy in Wilson’s disease [34]. Most other reports of
therapy or therapy trials in Wilson’s disease are basically anecdotal in that if patients
don’t return to the clinic after therapy initiation, they’re not used in the report.
We recently reported long-term follow-up studies on 141 patients treated with zinc
[34]; 109 patients have been treated for 5 years or longer, and 46 patients for 10 years
or longer. The efficacy data are excellent on all counts (34). The main problem has
been inadequate compliance with therapy by some patients, a problem in any long-
term trial. We detect noncompliance first by a urine zinc that is not as high as it should
be, namely, a minimum of 2 mg/ 24 hours. Later, if noncompliance continues, the
urine copper begins to increase. Such evidence results in a series of calls and letters
from our office, warning the patient about possible dangers of further noncompliance.
We also increase the frequency of monitoring. Serious noncompliance occurred in
about 10% of our patients, and periodic lessening of rigor in compliance occurred in
another 20% [34].
In addition to the long-term follow-up of maintenance therapy in symptomatic
patients who had originally been initiated on other therapies, our study included the
successful treatment of 20 presymptomatic patients from the beginning with zinc as
the sole therapy [34]. Since this is a genetic disease, it is important to screen other
family members, particularly full siblings, who are at a 25% risk for being affected in
a presymptomatic stage. These patients are considered as comparable to maintenance
phase patients and are treated only with zinc [32,34].
We have also treated women with Wilson’s disease through 18 pregnancies, using
zinc alone as the anticopper drug. Results have been good [34]. It is important for
these women to stay on anticopper therapy during pregnancy to protect themselves
against disease remission. Penicillamine and trientine are teratogenic in animals [41],
and penicillamine produces a teratogenic syndrome in human babies with a frequency
of about 5% [42, 43]. Zinc is nonteratogenic [44].
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We have successfully treated 30 pediatric Wilson’s disease patients with zinc as the
maintenance anticopper drug, the youngest being 3 years of age [34, 35]. We use a
reduced dose (25 mg × 2 until age 6, then 25 mg × 3 until 16 years of age or 125
pounds body weight, then 50 mg × 3). It is important to prevent overtreatment in
pediatric patients, because copper is required for bone growth. We monitor for over-
treatment in adults and pediatric patients, first by use of urine copper. When it reaches
low normal (below 35mg/ 24 hours), we reduce the dose. The first clinical indication
of copper deficiency is anemia.
The only toxicity of zinc we have encountered is mild to moderate abdominal
discomfort in about 10% of patients [34]. In many patients, this disappears within a
few days of therapy. In others, it is associated with taking the first dose upon arising.
For the latter patients we advise taking the first dose at midmorning. For stubborn
cases we allow the taking of offending doses with a little protein, such as lunchmeat,
cheese, or jello. Usually these maneuvers work well. Only one patient dropped out of
our study because of zinc intolerance.
Other authors have reported putative toxicities of zinc ranging from negative
effects on lipid metabolism [45–47] to worries about pancreatitis and negative effects
on immune function [46]. We have studied each of these areas [24,28,33] and find that
none are of concern in zinc therapy in Wilson’s disease.
There are also occasional reports of zinc treatment failures in Wilson’s disease [48,
49]. When looked at carefully, there is no evidence in these reports that the patient
was actually taking their zinc, and in one case there was actually evidence that they
were not taking it [48]. During our study, six of our patients died [34]. Three of these
deaths occurred from complications of acute or chronic aspiration and subsequent
infection. These data highlight the consequences of aspiration in patients with dys-
phagia. These patients should have had gastostomies, but refused. One patient died
from complications related to variceal bleeding, a significant risk in patients with
cirrhosis. One died in an accident, and one died from progressive liver failure. The
latter patient was suspected of noncompliance by the family. Six patients dropped out
of the study, and 10 were discharged because of lack of cooperation.
The Lemmon Company sponsored zinc acetate under the Orphan Drug Act. Later,
Lemmon was purchased by Gate Pharmaceutical. Based primarily upon our data, Gate
submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration
(FDA), and zinc acetate, under the trade name Galzint, was eventually approved for
maintenance therapy of Wilson’s disease in 1997.
Additional contributions to the use of zinc in Wilson’s disease have come from the
Netherlands. Schouwink [50] gave zinc to two Wilson’s disease patients as part of his
thesis work, although this work was never published in the general literature. Hoogen-
raad’s group [51–53] later followed up one of Schouwink’s patients and also gave
zinc, as the sulfate salt, to additional patients.
In summary of the status of zinc therapy for Wilson’s disease, zinc is taking its
place as the treatment of choice for maintenance therapy, as well as for the treatment
of the presymptomatic, pregnant, and pediatric patient, based on its complete efficacy
and lack of toxicity.
Treatment With Tetrathiomolybdate
Although zinc is ideal for maintenance therapy, it is too slow acting to be optimal
for patients presenting with acute copper toxicity. It takes an estimated 4–6 months of
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therapy for zinc to control copper and get copper levels below toxic thresholds.
Meanwhile, we discovered that penicillamine poses a huge risk to patients presenting
with brain-related symptomatology [54]. We found that about 50% of these patients
are made neurologically worse by penicillamine initiation, and half of those, or 25%
of the original sample, never recovered to pre-penicillamine baseline. The lives of
some of these patients were disastrously ruined. The mechanism of this worsening
may involve mobilization of hepatic copper and temporary further increases in brain
copper.
Trientine is an unknown with respect to its potential for causing neurological
worsening. On the one hand, it shares mechanism of action with penicillamine in that
it mobilizes copper into the bloodstream and causes increases in urinary copper. On
the other hand, it is a somewhat gentler drug than penicillamine. Experience is nil with
respect to using it as an initial drug in neurologically presenting patients.
Because of this therapeutic hiatus, we have developed tetrathiomolybdate (TM) for
the initial treatment of Wilson’s disease patients presenting with neurologic or psy-
chiatric symptoms. TM was discovered as a result of investigations in Australia and
New Zealand, initiated because ruminants grazing on certain pastures developed a
syndrome later recognized as copper deficiency [55–57]. In due course, the pastures
were found to be high in molybdenum (Mo), and Mo given to ruminants was then
shown to cause copper deficiency [58]. However, Mo given to rats was ineffective
[59,60]. Later it was realized that the rich sulfur metabolism in the rumen was
converting Mo into various thiomolybdates. Thiomolybdates given to rats were potent
anticopper agents, with the tetra-substituted derivative (TM), the most active [61].
Mason’s group has contributed much information on Mo, thiomolybdates, and copper
interactions [62,63].
TM is a very potent anticopper agent, and therefore very toxic, unless animals
being studied are copper-supplemented [64–66]. Copper supplementation eliminates
all side effects of TM, so all its toxicity is related solely to the production of copper
deficiency. In fact, no side effect of TM in animals or humans other than copper
deficiency has been observed. TM acts by forming a tripartite complex with copper
and protein [62,64–67]. Given with food, it prevents the absorption of food and
endogenously secreted copper. Give between meals it is absorbed into the blood and
complexes nonceruloplasmin plasma copper with itself and albumin. This copper is
nontoxic because it is unavailable for cellular uptake. The complexed copper is
believed to be primarily eliminated via the bile [62].
In our TM study in Wilson’s disease, we give TM in six divided doses, three times
a day with meals, and three times a day between meals [68–70]. Although we have
used higher doses in the past, currently we use 20 mg of TM in each dose. Higher
doses are more likely to produce a reversible anemia, which is due to bone marrow
depletion of copper. We give the drug for 8 weeks, during which time we carefully
monitor neurologic and speech function weekly with quantitative tests, to be sure
neurologic deterioration is not occurring. Zinc is started either at the beginning, or at
the 6 week point. At the end of 8 weeks, TM is stopped and the patient continues on
zinc therapy for maintenance.
Clinical results have been excellent with using TM in this manner [68–70]. Only
2 of 56 patients reached minimal scoring criteria for neurological worsening, and
these were minor. Clinical recovery begins about 5–6 months after therapy initiation
and continues for about 18 months. Almost all patients show substantial recovery, and
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often dramatic recovery. Residual deficits present 24 months after therapy initiation
are usually permanent.
In summary of the status of TM treatment for Wilson’s disease, it has proven to be
an ideal therapy for the initial treatment of neurologically presenting patients. It gains
control of copper quickly and without toxicity. So far, we have not found a commer-
cial sponsor for this drug. The market is tiny, keeping in mind that neurologically
presenting patients (estimated to about 200/year in the United States) are treated for
only 8 weeks. At present, we are doing a double- blind comparison of TM and
trientine for initial therapy in these patients, in collaboration with Dr. Michael Schil-
sky of Mount Sinai Medical Center, NY. If it turns out that trientine does not share
penicillamine’s risk of inducing neurological worsening, TM may not be needed.
However, if TM is significantly better than trientine in protecting function, it will be
important to find commercial sponsorship and put TM through the FDA approval
process.
This leaves as the only area of treatment not discussed, the treatment of patients
presenting with hepatic disease. First, if this type patient is in moderate to severe
hepatic failure, a decision needs to be made as to whether to recommend hepatic
transplantation or medical therapy. We find the prognostic index of Nazer et al. [71]
to be helpful as one guide in that decision-making process. If medical therapy is opted
for, we use a combination of trientine and zinc. Trientine is given to provide a
sizeable, fast, negative copper balance and zinc is given at this stage to induce hepatic
metallothionein, which will sequester hepatic copper and render it nontoxic.
In summary, with zinc and tetrathiomolybdate added to our therapeutic armamen-
torium, we now have very effective, nontoxic drugs to treat most phases of Wilson’s
disease. Zinc is the drug of choice for maintenance and for treatment of presymp-
tomatic, pregnant, and pediatric patients. Tetrathiomolybdate is excellent for the
patient presenting with neurologic disease. We have successfully used a combination
of trientine and zinc for the initial treatment of the patient presenting with hepatic
disease.
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